ArticleScientific reports2025
Investigation of the mechanism of chenodeoxycholic acid in treating acute lung injury through network pharmacology and experimental validation.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Oxidation-derived metabolites sustain the antioxidant network of quercetin.Journal of computer-aided molecular design · 2026Article
- Article
- NFKB1-targeted metabolites as novel therapeutic approaches for erectile dysfunction: evidence from gut microbiota network pharmacology and machine learning.Sexual medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Network pharmacology and molecular simulation techniques were employed to predict the potential targets and signaling pathways of chenodeoxycholic acid in the treatment of acute lung injury. Subsequently, its therapeutic effects on acute lung injury were preliminarily validated using animal experiments. The target of Chenodeoxycholic acid in the treatment of acute lung injury was predicted using network pharmacology. Key active ingredients and core targets were further validated using molecular docking studies. Lipopolysaccharide was used to establish a mouse model of acute lung injury to study the effect of chenodeoxycholic acid on acute lung injury. A total of 73 potential targets of Chenodeoxycholic acid for the treatment of acute lung injury were identified, primarily HSP90AA1, STAT3, HSP90AB1, EP300, and NFKB1. These core targets influence pathways associated with bile secretion, prostate cancer, and receptor activation in chemical carcinogenesis. These targets modulate various processes, including steroid metabolism, steroid biosynthesis, and intracellular receptor signaling pathways, thus contributing to the treatment of acute lung injury. Molecular docking results indicated that Chenodeoxycholic acid exhibited strong binding affinity for the core targets, with docking energies ranging from -5.6729 to -7.4138 kcal/mol. The reliability of the results was further verified by molecular dynamics simulations. Results from animal experiments demonstrated that Chenodeoxycholic acid effectively ameliorated pathological injury to lung tissue in mice with acute lung injury, decreased levels of IL-6 and TNF-α (P < 0.01), and increased levels of IL-10 (P < 0.01). The mRNA expression levels of EP300, HSP90AB1, MTOR, and STAT3 were inhibited, while the mRNA expression level of NR1H4 was significantly increased (P < 0.01). Chenodeoxycholic acid can effectively improve acute lung injury.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.